MCID: CHR417
MIFTS: 57

Chronic Graft Versus Host Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Chronic Graft Versus Host Disease

Summaries for Chronic Graft Versus Host Disease

NIH Rare Diseases : 52 Chronic graft versus host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms may include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damage to the lungs. The exact cause of chronic GVHD is unknown. It likely results from a complex immune-mediated interaction between the donor and recipient cells. Chronic GVHD is treated with prednisone or other similar anti-inflammatory or immunosuppressive medications.

MalaCards based summary : Chronic Graft Versus Host Disease, also known as chronic graft-versus-host disease, is related to graft-versus-host disease and acute graft versus host disease. An important gene associated with Chronic Graft Versus Host Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Panobinostat and Posaconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are poor wound healing and intermittent generalized erythematous papular rash

Related Diseases for Chronic Graft Versus Host Disease

Diseases in the Graft-Versus-Host Disease family:

Acute Graft Versus Host Disease Chronic Graft Versus Host Disease

Diseases related to Chronic Graft Versus Host Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 649)
# Related Disease Score Top Affiliating Genes
1 graft-versus-host disease 32.5 IL1A IL10 IFNG
2 acute graft versus host disease 31.9 IL2RA IL10 IFNG
3 bronchiolitis 31.3 IL1A IL10 IFNG
4 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.2 TNFSF13B IL10 IFNG
5 systemic scleroderma 30.9 IL10 IFNG CD4
6 myasthenia gravis 30.8 TNFSF13B IL10 IFNG
7 hypereosinophilic syndrome 30.7 IL2RA IL10 IFNG
8 glomerulonephritis 30.7 LCN2 CD79A ALB
9 membranous nephropathy 30.5 LCN2 CD79A ALB
10 dermatitis 30.5 IL1A IL10 IFNG
11 aspergillosis 30.4 IL1A IL10 IFNG
12 lymphopenia 30.4 IL2RA IL10 IFNG
13 red cell aplasia 30.4 IL2RA ALB
14 xerophthalmia 30.4 TNFSF13B CD4
15 viral hepatitis 30.4 IL10 IFNG ALB
16 chronic inflammatory demyelinating polyradiculoneuropathy 30.3 IL10 IFNG ALB
17 peritonitis 30.3 IL10 IFNG ALB
18 hemophagocytic lymphohistiocytosis 30.2 IL2RA IL10 IFNG
19 ocular cicatricial pemphigoid 30.2 CD79A CD36
20 constrictive pericarditis 30.2 IFNG ALB
21 polyradiculoneuropathy 30.2 IL10 IFNG ALB
22 hepatitis a 30.2 IL10 IFNG ALB
23 mixed connective tissue disease 30.2 TNFSF13B IL10 IFNG
24 pure red-cell aplasia 30.1 IL2RA ALB
25 juvenile arthritis 30.1 IL10 CD36
26 ileus 30.1 IL1A IL10 IFNG
27 gingivitis 30.1 IL1A IL10 IFNG
28 autoimmune disease 30.1 TNFSF13B IL2RA IL1A IL10 IFNG CD79A
29 lung disease 30.0 IL1A IL10 IFNG ALB
30 vasculitis 30.0 TNFSF13B LCN2 IL10 CD79A
31 stomatitis 30.0 IL10 IFNG CD4
32 nocardiosis 29.9 IFNG CD4
33 hemorrhagic cystitis 29.9 CD4 ALB
34 immunoglobulin alpha deficiency 29.9 TNFSF13B CD79A CD4
35 mumps 29.9 IL2RA IL10 IFNG
36 rubella 29.9 IL2RA IL10 IFNG
37 sjogren syndrome 29.8 TNFSF13B IL2RA IL10 CD79A
38 iridocyclitis 29.8 IL10 CD4
39 uveitis 29.8 IL2RA IL1A IL10 IFNG
40 mucormycosis 29.8 IFNG CD4
41 cryoglobulinemia 29.8 TNFSF13B IL10 IFNG CD79A
42 purpura 29.8 TNFSF13B IL10 IFNG CD79A
43 meningitis 29.8 IL1A IL10 IFNG ALB
44 exanthem 29.7 IL10 IFNG CD4 ALB
45 peripheral nervous system disease 29.7 IL10 IFNG CD4 ALB
46 invasive aspergillosis 29.6 IL10 IFNG CD4
47 herpes zoster 29.6 IL10 IFNG CD4
48 chickenpox 29.6 IL10 IFNG CD4 ALB
49 alopecia areata 29.6 IL2RA IL1A IL10 IFNG
50 diphtheria 29.6 IL2RA IFNG ALB

Graphical network of the top 20 diseases related to Chronic Graft Versus Host Disease:



Diseases related to Chronic Graft Versus Host Disease

Symptoms & Phenotypes for Chronic Graft Versus Host Disease

Human phenotypes related to Chronic Graft Versus Host Disease:

58 31 (show top 50) (show all 55)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 poor wound healing 58 31 hallmark (90%) Very frequent (99-80%) HP:0001058
2 intermittent generalized erythematous papular rash 58 31 hallmark (90%) Very frequent (99-80%) HP:0007432
3 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
4 erythema 58 31 frequent (33%) Frequent (79-30%) HP:0010783
5 xerostomia 58 31 frequent (33%) Frequent (79-30%) HP:0000217
6 abnormality of skin pigmentation 58 31 frequent (33%) Frequent (79-30%) HP:0001000
7 elevated hepatic transaminase 58 31 frequent (33%) Frequent (79-30%) HP:0002910
8 alopecia 58 31 frequent (33%) Frequent (79-30%) HP:0001596
9 keratoconjunctivitis sicca 58 31 frequent (33%) Frequent (79-30%) HP:0001097
10 recurrent infections 58 31 frequent (33%) Frequent (79-30%) HP:0002719
11 nail dystrophy 58 31 frequent (33%) Frequent (79-30%) HP:0008404
12 bronchiectasis 58 31 frequent (33%) Frequent (79-30%) HP:0002110
13 onycholysis 58 31 frequent (33%) Frequent (79-30%) HP:0001806
14 recurrent corneal erosions 58 31 frequent (33%) Frequent (79-30%) HP:0000495
15 food intolerance 58 31 frequent (33%) Frequent (79-30%) HP:0012537
16 arthritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001369
17 flexion contracture 58 31 occasional (7.5%) Occasional (29-5%) HP:0001371
18 gastroesophageal reflux 58 31 occasional (7.5%) Occasional (29-5%) HP:0002020
19 muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0001324
20 dysphagia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002015
21 dyspnea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002094
22 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
23 arthralgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002829
24 skin vesicle 58 31 occasional (7.5%) Occasional (29-5%) HP:0200037
25 skin ulcer 58 31 occasional (7.5%) Occasional (29-5%) HP:0200042
26 ascites 58 31 occasional (7.5%) Occasional (29-5%) HP:0001541
27 hematuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000790
28 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
29 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
30 myalgia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003326
31 cough 58 31 occasional (7.5%) Occasional (29-5%) HP:0012735
32 chest pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0100749
33 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
34 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
35 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
36 pneumothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0002107
37 pancytopenia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001876
38 fasciitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0100537
39 phimosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001741
40 esophageal stricture 58 31 occasional (7.5%) Occasional (29-5%) HP:0002043
41 urinary bladder inflammation 58 31 occasional (7.5%) Occasional (29-5%) HP:0100577
42 esophageal ulceration 58 31 occasional (7.5%) Occasional (29-5%) HP:0004791
43 morphea 58 31 occasional (7.5%) Occasional (29-5%) HP:0012344
44 nausea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002018
45 wheezing 58 31 occasional (7.5%) Occasional (29-5%) HP:0030828
46 bronchiolitis obliterans 58 31 occasional (7.5%) Occasional (29-5%) HP:0011946
47 entrapment neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0012181
48 abnormal vagina morphology 31 occasional (7.5%) HP:0000142
49 pulmonary obstruction 31 occasional (7.5%) HP:0006536
50 thickened skin 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Chronic Graft Versus Host Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.02 CD36 CD4 CD79A IFNG IL10 IL1A
2 cardiovascular system MP:0005385 10 ALB CD36 IFNG IL10 IL1A IL2RA
3 homeostasis/metabolism MP:0005376 9.97 ALB CD36 CD4 CD79A IFNG IL10
4 immune system MP:0005387 9.96 ALB CD36 CD4 CD79A IFNG IL10
5 endocrine/exocrine gland MP:0005379 9.95 ALB CD36 CD4 IFNG IL10 IL2RA
6 digestive/alimentary MP:0005381 9.91 ALB CD36 CD4 IFNG IL10 IL2RA
7 liver/biliary system MP:0005370 9.63 ALB CD36 CD79A IFNG IL10 LCN2
8 neoplasm MP:0002006 9.35 ALB CD79A IFNG IL10 IL1A
9 no phenotypic analysis MP:0003012 9.02 CD4 CD79A IFNG IL10 LCN2

Drugs & Therapeutics for Chronic Graft Versus Host Disease

Drugs for Chronic Graft Versus Host Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 243)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Panobinostat Approved, Investigational Phase 4 404950-80-7 6918837
2
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
3
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
6 Histone Deacetylase Inhibitors Phase 4
7 Antiprotozoal Agents Phase 4
8 Antiparasitic Agents Phase 4
9 glucocorticoids Phase 4
10 Hormones Phase 4
11 Hormone Antagonists Phase 4
12 Pharmaceutical Solutions Phase 4
13 Cytochrome P-450 CYP3A Inhibitors Phase 4
14 Cytochrome P-450 Enzyme Inhibitors Phase 4
15
Hydroxyitraconazole Phase 4
16
Idarubicin Approved Phase 3 58957-92-9 42890
17
Hydroxychloroquine Approved Phase 3 118-42-3 3652
18
Clobetasol Approved, Experimental, Investigational Phase 3 25122-41-2, 25122-46-7 32798 5311051
19
Budesonide Approved Phase 3 51333-22-3 63006 5281004
20
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
21
Acyclovir Approved Phase 3 59277-89-3 2022
22
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
23
Atorvastatin Approved Phase 3 134523-00-5 60823
24
Peginterferon alfa-2b Approved Phase 2, Phase 3 99210-65-8, 215647-85-1
25
Sodium citrate Approved, Investigational Phase 3 68-04-2
26
Azithromycin Approved Phase 3 83905-01-5 447043 55185
27
Daunorubicin Approved Phase 3 20830-81-3 30323
28
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
29
Hydroxyurea Approved Phase 3 127-07-1 3657
30
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
31
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
32
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
33
Inolimomab Investigational Phase 3 152981-31-2 5785
34 Antimalarials Phase 3
35 Respiratory System Agents Phase 3
36 Anti-Asthmatic Agents Phase 3
37 Bronchodilator Agents Phase 3
38 Muromonab-CD3 Phase 3
39 Lipid Regulating Agents Phase 3
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 3
41 Hypolipidemic Agents Phase 3
42 Anticholesteremic Agents Phase 3
43 Interferon alpha-2 Phase 2, Phase 3
44 Interferon-alpha Phase 2, Phase 3
45 interferons Phase 2, Phase 3
46 Protein Kinase Inhibitors Phase 3
47 Imatinib Mesylate Phase 3 220127-57-1 123596
48 Citrate Phase 3
49 Janus Kinase Inhibitors Phase 3
50 Anticoagulants Phase 3

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies Unknown status NCT01856803 Phase 4 anti thymoglobulin
2 Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Unknown status NCT02677181 Phase 4 ATG;CsA;mycophenolate mofetil;Methotrexate
3 Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD Completed NCT00574470 Phase 4 daclizumab, infliximab
4 ATG Used in Allogeneic Hematopoietic Stem Cell Transplantation From HLA-matched Sibling Donor as GVHD Prophylaxis Recruiting NCT04203108 Phase 4 ATG;CsA;MTX;MMF
5 Pharmacokinetics Study of Posaconazole in Haematology Patients Receiving Standard of Care Treatment With Oral Posaconazole Prophylaxis for Invasive Fungal Infection Recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
6 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti-human Thymoglobulin;Placebo
7 Open Label, Multi-center, Phase IV Study of Ruxolitinib or Ruxolitinib and Panobinostat Combination, for Patients Who Have Completed Prior Global Novartis or Incyte Sponsored Studies Recruiting NCT02386800 Phase 4 ruxolitinib tablets or oral pediatric formulation, panobinostat capsules;ruxolitinib tablets or oral pediatric formulation
8 A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation Not yet recruiting NCT03190733 Phase 4 ATG
9 Evaluation of Antifungal Prophylaxis Against Invasive Fungal Infections During Corticosteroid Containing Therapy for Graft-versus-host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01282879 Phase 4 Itraconazole
10 Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China. Unknown status NCT02291770 Phase 3
11 Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease Unknown status NCT01526850 Phase 2, Phase 3 Cyclosporine and Glucocorticoid
12 A Randomized Trial of Thymoglobulin to Prevent Chronic Graft Versus Host Disease in Patients Undergoing Hematopoietic Progenitor Cell Transplantation (HPCT) From Unrelated Donors Unknown status NCT01217723 Phase 3
13 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
14 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423500 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG
15 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
16 Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT Unknown status NCT02178683 Phase 3 Tacrolimus and MMF.
17 A Phase III Randomized Trial of G-CSF Stimulated Bone Marrow vs. Conventional Bone Marrow as a Stem Cell Source In Matched Sibling Donor Transplantation Unknown status NCT00450450 Phase 3
18 Multi-Centre Prospective Randomized Study on the Use of Two Different Doses of Rabbit Anti-Thymocyte Globulin for GVHD Prevention in Paediatric Patients With Haematological Malignancies Given an Unrelated Donor Haematopoietic Stem Cell Transplantation Unknown status NCT00934557 Phase 3 ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius;ATG Fresenius
19 Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease Completed NCT00031824 Phase 3 cyclosporine;hydroxychloroquine;prednisone;tacrolimus
20 A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801) Completed NCT01106833 Phase 2, Phase 3 Sirolimus + calcineurin inhibitor + prednisone;Sirolimus + prednisone
21 Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study Completed NCT00678275 Phase 3 ATG FRESENIUS (Anti-Lymphocyte-Globulin);ATG FRESENIUS (Anti-Lymphocyte-Globulin)
22 A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT01020175 Phase 3
23 Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT01699412 Phase 3 Clobetasol;Dexamethasone
24 A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201) Completed NCT00075816 Phase 3
25 T-Cell Depletion in Unrelated Donor Marrow Transplantation Completed NCT00000591 Phase 3
26 An Investigator Initiated Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Valganciclovir in Prevention of Cytomegalovirus Reactivation Following Allogeneic Stem Cell Transplantation Completed NCT00330018 Phase 3 Valganciclovir;Acyclovir
27 A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicenter Study. Completed NCT00993343 Phase 3 Sirolimus/tacrolimus;cyclosporine/methotrexate
28 A PHASE III RANDOMIZED STUDY COMPARING G-CSF MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH MARROW AS THE SOURCE OF STEM CELLS FOR ALLOGENEIC TRANSPLANTS FROM HLA IDENTICAL, RELATED DONORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA Completed NCT00002789 Phase 3 busulfan;cyclophosphamide;cyclosporine;methotrexate
29 Hematopoietic Stem Cell Transplant For Patients With Dyskeratosis Congenita and Severe Aplastic Anemia Completed NCT00455312 Phase 2, Phase 3 Campath 1H;Cyclophosphamide;Fludarabine;antithymocyte globulin;Methylprednisolone
30 Treatment of Chronic Granulomatous Disease With Allogeneic Stem Cell Transplantation Versus Standard of Care Completed NCT00023192 Phase 3 T-Cell Depleted & CD34+Select/w/StemCell Enriched Product
31 Randomized Study Comparing i.v. Busulfan (Busilvex®) Plus Fludarabine (BuFlu) Versus Busilvex® Plus Cyclophosphamide (BuCy2) as Conditioning Regimens Prior AlloHSCT in Patients (Age >= 40 and =<65 Years) With AML in Complete Remission. Completed NCT01191957 Phase 3 Busulphan plus Cyclophosphamide;Busulphan plus Fludarabine
32 Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors Completed NCT01295710 Phase 3
33 Double-blind, Randomised, Placebo-controlled Multicentre Phase III Clinical Study Followed by Open-label Phase on the Efficacy and Tolerability of Budesonide 3 mg Effervescent Tablet in Patients With Resistant Oral Chronic GvHD Completed NCT00887263 Phase 3 Budesonide;Placebo
34 Prophylaxis Trial in High Risk Allogenic Stem Cell Transplant Recipients With Graft vs. Host Disease Completed NCT00034645 Phase 3 Posaconazole oral suspension
35 Nonmyeloablative Allogeneic Stem Cell Transplantation in Elderly Patients With Hematological Malignancies:Results From the GITMO (Gruppo Italiano Trapianto Midollo Osseo)Multicenter Prospective Clinical Trial Completed NCT00382759 Phase 2, Phase 3
36 A Prospective Randomized, Controlled Pilot Study in Order to Evaluate the Place of Thymoglobuline in Non-myeloablative Allogeneic Hemapoietic Stem-cell Transplantation (NST) Completed NCT00130754 Phase 3 Thymoglobuline
37 Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens Completed NCT00822393 Phase 3 Busulfan;Treosulfan
38 Treatment of Acute Graft vs. Host Disease With Steroids Plus Daclizumab (Zenapax) or Placebo Completed NCT00053976 Phase 3 methylprednisolone;Placebo
39 A Randomized Trial of Sirolimus-Based Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation in Relapsed Acute Lymphoblastic Leukemia Completed NCT00382109 Phase 3 thiotepa;cyclophosphamide;tacrolimus;methotrexate;sirolimus
40 A Multi-Center, Open Label, Randomized, Active Controlled Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Processed Unrelated Bone Marrow in Patients With Acute or Chronic Leukemia Completed NCT00004255 Phase 2, Phase 3 cyclophosphamide;fludarabine phosphate;methylprednisolone;tacrolimus
41 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
42 Hematopoietic Stem Cell Transplantation Using Matched Unrelated Donor Peripheral Blood or Bone Marrow for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
43 Haploidentical Stem Cell Transplantation Utilizing Purified CD34+ Hematopoietic Cells for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
44 GRAVITAS-309: A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease Recruiting NCT03584516 Phase 3 Itacitinib;Placebo;Methylprednisolone;Prednisone
45 Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors Recruiting NCT03066466 Phase 3 Atorvastatin;Methotrexate;Tacrolimus
46 Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial Recruiting NCT03818334 Phase 2, Phase 3 Cyclophosphamide;ATG
47 BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies Recruiting NCT02600208 Phase 2, Phase 3
48 Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation Recruiting NCT02634294 Phase 2, Phase 3 Peg interferon alfa-2b
49 Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE) Active, not recruiting NCT02959944 Phase 3 ibrutinib;Placebo;Prednisone
50 A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) Active, not recruiting NCT03474679 Phase 3 Ibrutinib

Search NIH Clinical Center for Chronic Graft Versus Host Disease

Genetic Tests for Chronic Graft Versus Host Disease

Anatomical Context for Chronic Graft Versus Host Disease

MalaCards organs/tissues related to Chronic Graft Versus Host Disease:

40
Bone, Bone Marrow, T Cells, Myeloid, Skin, B Cells, Eye

Publications for Chronic Graft Versus Host Disease

Articles related to Chronic Graft Versus Host Disease:

(show top 50) (show all 3869)
# Title Authors PMID Year
1
Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. 54 61
19285638 2009
2
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. 54 61
16239431 2006
3
Granulocyte colony-stimulating factor--primed allogeneic bone marrow transplants: capturing the advantages of blood stem cell transplants without increased risk of chronic graft-versus-host disease. 54 61
10975509 2000
4
Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients. 61
32417677 2020
5
Extracellular vesicles derived from mesenchymal stem cells prevent skin fibrosis in the cGVHD mouse model by suppressing the activation of macrophages and B cells immune response. 61
32402950 2020
6
Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. 61
32389803 2020
7
[Cutaneous manifestations of acute and chronic graft-versus-host disease after allogeneic stem cell transplantation]. 61
32424469 2020
8
FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease. 61
32100182 2020
9
Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. 61
32283185 2020
10
Evaluation of quality of life and its influencing factors after transplantation of leukemia patients based on SF-36 score: a cohort study. 61
32219707 2020
11
A prospective evaluation on the interaction of fluconazole and voriconazole on serum concentrations of budesonide in patients treated for gastrointestinal GVHD. 61
31953533 2020
12
Impact of Guideline-Driven Approach in Follow-Up of Long-Term Complications After Allogeneic Hematopoietic Cell Transplant: Single Center Experience. 61
30251944 2020
13
Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. 61
32492155 2020
14
Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. 61
32154926 2020
15
The management of gynecological complications in long-term survivors after allogeneic hematopoietic cell transplantation-a single-center real-life experience. 61
32342133 2020
16
cGVHD in pediatric haplo-HSCT. 61
32504861 2020
17
Efficacy of minimal residual disease driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicentric trial. 61
32527951 2020
18
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. 61
32469169 2020
19
Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. 61
32556712 2020
20
Impact of graft-versus-host disease on the clinical outcome of allogeneic hematopoietic stem cell transplantation for non-malignant diseases. 61
32052319 2020
21
Ruxolitinib is an effective steroid sparing agent in bronchiolitis obliterans due to chronic graft-versus-host-disease. 61
31484991 2020
22
Sarcopenia among patients after allogeneic hematopoietic stem cell transplantation and the impact of chronic graft-versus-host disease. 61
32507973 2020
23
Ezh2-mediated epigenetic modification is required for allogeneic T cell-induced lupus disease. 61
32503684 2020
24
Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. 61
32428736 2020
25
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology 61
32519831 2020
26
Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? 61
32034776 2020
27
Mechanistic Basis of ex Vivo Umbilical Cord Blood Stem Progenitor Cell Expansion. 61
32424674 2020
28
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. 61
32422254 2020
29
Correction of Severe Myelofibrosis, Impaired Platelet Functions and Abnormalities in a Patient with Gray Platelet Syndrome Successfully Treated by Stem Cell Transplantation. 61
31502501 2020
30
Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Juvenile Myelomonocytic Leukemia: A Report from the Japan Society for Hematopoietic Cell Transplantation. 61
31790827 2020
31
Genetic Profile and Microsatellite Instability in a Case of Secondary Esophageal Squamous Cell Carcinoma 12 Years After Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. 61
30499911 2020
32
Role of pretransplant anti-thymocyte globulin in matched sibling donor stem cell transplantation after reduced intensity conditioning for myelodysplastic syndrome. 61
31957068 2020
33
Evolving Therapeutic Options for Chronic Graft-versus-Host Disease. 61
32441379 2020
34
Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. 61
32382059 2020
35
Risk factors associated with severity of dry eye syndrome in ocular graft-versus-host disease. 61
32439193 2020
36
Topical tacrolimus for refractory superficial mucoceles in a patient with chronic graft versus host disease. 61
32382636 2020
37
Expansion of circulating CD49b+LAG3+ type 1 regulatory T (Tr1) cells in human chronic graft-versus-host disease. 61
32428542 2020
38
Ixazomib for Treatment of Refractory Chronic Graft- versus-Host Disease: A Chronic GVHD Consortium Phase II Trial. 61
32464285 2020
39
Erratum to "Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation"[Experimental Hematology 74 (2019) 25-32]. 61
32325014 2020
40
Nilotinib Treatment of Patients Affected by Chronic Graft-versus-Host Disease Reduces Collagen Production and Skin Fibrosis by Downmodulating the TGF-β and p-SMAD Pathway. 61
32006713 2020
41
Male Gonadal Function after Allogeneic Hematopoietic Stem Cell Transplantation in Childhood: A Cross-Sectional, Population-Based Study. 61
32447044 2020
42
Ocular Complications in School-Age Children and Adolescents after Allogeneic Bone Marrow Transplantation. 61
32006482 2020
43
Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin. 61
31324882 2020
44
Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: A cohort study in a high endemic area. 61
30082145 2020
45
Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. 61
32227211 2020
46
Psychometric properties of the Activities Ccale for Kids-performance after allogeneic hematopoietic stem cell transplantation in adolescents and children : Results of a prospective study on behalf of the German-Austrian-Swiss GVHD Consortium. 61
32246210 2020
47
Hyposplenism, Hashimoto's Autoimmune Thyroiditis and Overlap Syndrome (Celiac Disease and Autoimmune Hepatitis Type 1). 61
32563569 2020
48
Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. 61
31917270 2020
49
[Efficacy and safety of ruxolitinib in the salvage treatment of chronic graft versus-host disease]. 61
32344495 2020
50
Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. 61
31762357 2020

Variations for Chronic Graft Versus Host Disease

Expression for Chronic Graft Versus Host Disease

Search GEO for disease gene expression data for Chronic Graft Versus Host Disease.

Pathways for Chronic Graft Versus Host Disease

Pathways related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 TNFSF13B LCN2 IL2RA IL1A IL10 IFNG
2
Show member pathways
13.46 TNFSF13B IL2RA IL1A IL10 IFNG CD4
3
Show member pathways
13.33 TNFSF13B IL2RA IL1A IL10 IFNG CD4
4
Show member pathways
13.09 TNFSF13B IL2RA IL1A IL10 CD4
5
Show member pathways
12.87 TNFSF13B LCN2 IL2RA IL1A IL10 IFNG
6
Show member pathways
12.54 TNFSF13B IL2RA IL1A IL10 IFNG CD4
7
Show member pathways
12.47 IL2RA IL10 IFNG CD79A CD4
8
Show member pathways
12.43 IL1A IL10 IFNG CD4
9
Show member pathways
12.41 IL2RA IL1A IL10 IFNG CD4
10 12.35 TNFSF13B IL2RA IL10 IFNG CD79A
11
Show member pathways
12.09 IL1A IL10 IFNG
12
Show member pathways
12.09 IL2RA IL1A IL10 IFNG
13 12.06 IL1A IL10 IFNG
14 11.86 TNFSF13B IL1A IFNG
15
Show member pathways
11.83 IL2RA IFNG CD4
16 11.81 LCN2 IL1A IL10 CD36
17
Show member pathways
11.79 IL10 IFNG CD4
18 11.71 TNFSF13B IL1A IFNG
19 11.7 IL2RA IL1A CD4 CD36
20 11.6 IL10 IFNG CD4
21 11.57 IL2RA IL10 IFNG CD4
22 11.42 IL10 IFNG CD36
23
Show member pathways
11.27 IL2RA IL10 IFNG
24 11.22 IL2RA IL10 IFNG CD4
25 11.16 IL2RA IL10 IFNG CD79A CD4 CD36
26 11.12 IL2RA IFNG CD4
27
Show member pathways
11.11 IL2RA IFNG
28 11.05 IL10 IFNG
29 10.92 IL1A IFNG
30 10.72 IL1A IL10 IFNG CD4

GO Terms for Chronic Graft Versus Host Disease

Cellular components related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 IL2RA CD79A CD4 CD36
2 extracellular space GO:0005615 9.17 TNFSF13B LCN2 IL1A IL10 IFNG CD36

Biological processes related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 LCN2 IL1A IFNG CD36
2 immune system process GO:0002376 9.8 TNFSF13B LCN2 IL2RA CD79A CD4
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.73 IL1A CD4 CD36
4 cellular response to lipopolysaccharide GO:0071222 9.62 LCN2 IL1A IL10 CD36
5 positive regulation of interleukin-12 production GO:0032735 9.55 IFNG CD36
6 cell surface receptor signaling pathway GO:0007166 9.55 IL2RA IFNG CD79A CD4 CD36
7 inflammatory response to antigenic stimulus GO:0002437 9.54 IL2RA IL1A
8 positive regulation of T cell proliferation GO:0042102 9.54 TNFSF13B IL2RA CD4
9 positive regulation of tumor necrosis factor secretion GO:1904469 9.52 IL1A IFNG
10 macrophage differentiation GO:0030225 9.51 IFNG CD4
11 regulation of regulatory T cell differentiation GO:0045589 9.48 IL2RA IFNG
12 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.46 IL1A CD4
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.43 IL10 IFNG
14 positive regulation of cytokine secretion GO:0050715 9.43 IL1A IL10 IFNG
15 cytokine-mediated signaling pathway GO:0019221 9.43 LCN2 IL2RA IL1A IL10 CD4 CD36
16 immune response GO:0006955 9.17 TNFSF13B IL2RA IL1A IL10 IFNG CD4

Molecular functions related to Chronic Graft Versus Host Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 TNFSF13B IL1A IL10 IFNG
2 enterobactin binding GO:1903981 8.62 LCN2 ALB

Sources for Chronic Graft Versus Host Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....